Abingdon Health Plc (ABDXF) 株価予測

Abingdon Health Plc engages in the development, manufacturing, and distribution of diagnostic devices and provide consultancy services to businesses in the diagnostics sector. The company is headquartered in York, North Yorkshire and currently employs 121 full-time employees. The company went IPO on 2020-12-15. The firm is an international developer, manufacturer and distributor of effective rapid tests. Its CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Its CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, and others. Its Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests. The Abingdon Simply Test’s other selected self-test products, such as the saliva pregnancy test, Salistick, which is sold through international distributors and through other channels in the United Kingdom and Ireland, such as pharmacy chains.